Bobin Hu1,2, Rongming Wang1,2, Jiaxin Fu1,2, Minghua Su1,2, Man Du1,2, Yu Liu1,2, Huijiao Li1,2, Huiwen Wang1,2, Fengmin Lu3, Jianning Jiang1,2. 1. Department of Infectious Disease, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. 2. Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Nanning, China. 3. Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Abstract
BACKGROUND AND AIM: The aim of this study is to investigate the impact of hepatitis B virus (HBV) S gene integration on serum hepatitis B surface antigen (HBsAg) levels in chronic hepatitis B with long-term nucleos(t)ide analogue (NUC) therapy. METHODS: Chronic hepatitis B patients who performed liver biopsy at baseline and treated with long-term NUC therapy were recruited. The integration of HBV S gene in baseline liver biopsy specimen was detected by Alu polymerase chain reaction method. Serum HBsAg levels were measured at baseline and the second year and the fourth year after NUC therapy by Roche reagent, respectively. Serum HBsAg levels between HBV S gene integrated group and nonintegrated group were compared and analyzed. RESULTS: Seventy patients were eligible for this study. Among them, 11 (15.7%) were found to have HBV S gene integration in their baseline liver biopsy specimens. Similar significant decrease of HBsAg levels was found in both integrated and nonintegrated groups (2.63 vs 2.65 log IU/mL, P = 0.478) after the first 2 years of NUC therapy. Thereafter, the decrease of HBsAg level from 2 to 4 years after therapy was largely unchanged in integrated group as compared with that of nonintegrated group (0.1 vs 2.53 log IU/mL, P = 0.002), with statistical difference. CONCLUSIONS: Serum HBsAg could be originated from the expression of the integrated HBV S gene in patients with S gene integration, which implicated the limitations when regarding HBsAg as a surrogate biomarker of covalently closed circular DNA activity and as an indicator of safe NUC discontinuation.
BACKGROUND AND AIM: The aim of this study is to investigate the impact of hepatitis B virus (HBV) S gene integration on serum hepatitis B surface antigen (HBsAg) levels in chronic hepatitis B with long-term nucleos(t)ide analogue (NUC) therapy. METHODS: Chronic hepatitis Bpatients who performed liver biopsy at baseline and treated with long-term NUC therapy were recruited. The integration of HBV S gene in baseline liver biopsy specimen was detected by Alu polymerase chain reaction method. Serum HBsAg levels were measured at baseline and the second year and the fourth year after NUC therapy by Roche reagent, respectively. Serum HBsAg levels between HBV S gene integrated group and nonintegrated group were compared and analyzed. RESULTS: Seventy patients were eligible for this study. Among them, 11 (15.7%) were found to have HBV S gene integration in their baseline liver biopsy specimens. Similar significant decrease of HBsAg levels was found in both integrated and nonintegrated groups (2.63 vs 2.65 log IU/mL, P = 0.478) after the first 2 years of NUC therapy. Thereafter, the decrease of HBsAg level from 2 to 4 years after therapy was largely unchanged in integrated group as compared with that of nonintegrated group (0.1 vs 2.53 log IU/mL, P = 0.002), with statistical difference. CONCLUSIONS: Serum HBsAg could be originated from the expression of the integrated HBV S gene in patients with S gene integration, which implicated the limitations when regarding HBsAg as a surrogate biomarker of covalently closed circular DNA activity and as an indicator of safe NUC discontinuation.
Authors: Gustaf E Rydell; Simon B Larsson; Kasthuri Prakash; Maria Andersson; Heléne Norder; Kristoffer Hellstrand; Gunnar Norkrans; Magnus Lindh Journal: J Infect Dis Date: 2022-06-01 Impact factor: 7.759
Authors: Robin Erken; Vladimir Loukachov; Karel van Dort; Anne van den Hurk; R Bart Takkenberg; Anniki de Niet; Louis Jansen; Sophie Willemse; Henk Reesink; Neeltje Kootstra Journal: Hepatology Date: 2022-02-14 Impact factor: 17.298
Authors: Romina Salpini; Stefano D'Anna; Livia Benedetti; Lorenzo Piermatteo; Upkar Gill; Valentina Svicher; Patrick T F Kennedy Journal: Front Microbiol Date: 2022-09-02 Impact factor: 6.064